Efficacy of high intensity laser therapy in patellofemoral pain syndrome

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

TCTR

Registry ID

TCTR20220418007

Enrollment

Registered

2022-04-18

Start date

2019-09-25

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with patellofemoral pain syndrome high intensity laser therapy, patellofemoral pain syndrome, anterior knee pain

Interventions

High intensity laser therapy group received high intensity laser therapy from Hilterapia, HIRO TT (Pulsed high power Nd:YAG laser, wavelength 1064 nm, peak Power (max): 3 kW, Average power (max): 10.5

10-second hold, 3 times a day, hamstrings muscle stretching for 10-second hold twice daily and lifestyle modification,The control group received a sham laser by switching the laser cable that made the

10-second hold, 3 times a day, hamstrings muscle stretching for 10-second hold twice daily and lifestyle modification

Experimental Device,Sham Comparator Device

High intensity laser therapy group,Control group

Eligibility

Sex/Gender

All

Age

20 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1. Anterior knee pain for at least 3 months, 2. 2 or more daily activities that induced knee pain: standing with bending the knee, ascending or descending the stairs, kneeling, jumping or sitting in a knee bending position for an amount of time or contracting quadriceps muscle, 3. Positive patella grind test, 4. 3 or more of Visual Analogue Scale

Exclusion criteria

Exclusion criteria: 1. History of knee surgery, 2. Recent knee trauma or infection or any signs of knee OA, 3. Recently used corticosteroids and/or anti-inflammatory drugs, 4. Severe neurological or cardiovascular disorders, 5. Contraindication for laser therapy

Design outcomes

Primary

Measure	Time frame
Pain at pretreatment and 3, 6, 12 weeks posttreatment Visual Analogue Scale	—

Secondary

Measure	Time frame
Functional outcome at pretreatment and 3, 6, 12 weeks posttreatment Kujala scoring questionnaire,Quality of life at pretreatment and 3, 6, 12 weeks posttreatment Short Form-36 health survey version 2.0	—

Countries

Thailand

Contacts

Public ContactPeerada Eurcherdkul

Faculty of medicine Ramathibodi, Mahidol university

eurpeerada@gmail.com0922720652

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026